Illumina, Inc. vs Snap On Incorporated — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: Illumina, Inc. is far larger — about 2.2× Snap On Incorporated's market cap, and Snap On Incorporated pays a 2.72% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Snap On Incorporated for 37 Days on average.
| ILMN | SNA | |
|---|---|---|
Market Cap | $39.95B | $18.56B |
Volume | 3,169,503 | 401,326 |
Sector | Health | Industrials |
52-Week High | $293.69 | $419.31 |
52-Week Low | $91.00 | $327.33 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $41.31B | $18.20B |
Dividend Yield | — | 2.72% |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Snap-On Incorporated (SNA) trades at $358.88, down 0.28% on the day, with a bearish technical signal from moving averages and oscillators. The company reported solid fundamentals with a 19.6% net income margin and a 17.58% ROE for 2025. Recent earnings show a mix of beats and a miss, with Q3 2026 results pending. Analyst consensus is bullish with a $449 price target, but technical indicators suggest near-term caution amid institutional position adjustments.
The outlook for SNA is supported by strong profitability and analyst optimism, but faces headwinds from technical bearishness and valuation risks. Investment opportunity lies in execution of RCI initiatives and diagnostic segment growth, while risks include integration costs from acquisitions and softer OEM demand. The stock's premium valuation requires sustained earnings growth to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →